Looking to sell PathAI stock or options?Contact us
PathAI has developed an artificial intelligence-powered research platform designed to enhance the precision and efficiency of cancer diagnosis and therapy. The platform utilizes machine and deep learning methods to analyze large aggregated datasets, which allows for the identification of cancer cells individually. This, in turn, enables pathologists to diagnose cancer patients with speed and accuracy.
Waikit Lau, Merck Global Health Innovation Fund, Labcorp Ventures, Refactor Capital, DHVC, Mike Volpe, Innospark Ventures, General Catalyst, Pillar VC, Hercules Capital, Ad Super, Operator VC, 8VC, Polaris Partners, Biospring Partners, Bristol-Myers Squibb, D1 Capital Partners, KdT Ventures, HighSage Ventures, Fairhaven Capital Partners, Koch Disruptive Technologies, Kaiser Permanente.
We have an even better solution: The Collective Exchange Fund
Get in touch and see if we can help you